Dalpiciclib in combination with letrozole/anastrozole or fulvestrant in HR-positive and HER2-negative advanced breast cancer: results from a phase Ib study

Background: Dalpiciclib is a novel cyclin-dependent kinase 4/6 inhibitor which showed tolerability and preliminary efficacy as monotherapy for pretreated advanced breast cancer (BC). Objectives: To further assess dalpiciclib with endocrine therapy (ET) in hormone receptor (HR)-positive/human epiderm...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	Qingyuan Zhang, Pin Zhang, Min Yan, Xi Yan, Xian Wang, Yuanting Gu, Xiujuan Qu, Shaorong Li, Guoying Xu, Xiaoyu Zhu, Binghe Xu
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	SAGE Publishing 2024-08-01
סדרה:	Therapeutic Advances in Medical Oncology
גישה מקוונת:	https://doi.org/10.1177/17588359241273026
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!